Next Article in Journal
Usefulness of a Telemedicine Program in Refractory Older Congestive Heart Failure Patients
Next Article in Special Issue
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
Previous Article in Journal
PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment
Previous Article in Special Issue
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Article Menu

Export Article

Open AccessArticle
Diseases 2018, 6(1), 9; doi:10.3390/diseases6010009

Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome

Department of Pharmacology, Toxicology, and Medicine, College of Medicine Al-Mustansiriyah University, P.O. Box 14132 Baghdad, Iraq
Author to whom correspondence should be addressed.
Received: 5 December 2017 / Revised: 5 January 2018 / Accepted: 8 January 2018 / Published: 16 January 2018
View Full-Text   |   Download PDF [903 KB, uploaded 16 January 2018]   |  


Adipose tissue-derived serine protease inhibitor (vaspin), which has endocrine and local roles in atherosclerosis growth, is also synthesized by adipose tissue; it was found that vaspin was negatively correlated with blood pressure in obese patients, while vaspin levels were decreased in endothelial dysfunction. The aim of the present study was to determine rosuvastatin modulation effects on serum vaspin levels in acute coronary syndrome (ACS) with class I obesity. A total number of seventy patients with acute coronary syndrome previously and currently treated with rosuvastatin was compared to 40 patients with IHD not treated by rosuvastatin as a control. Vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Additionally, in the rosuvastatin-treated group, patients with STEMI showed higher vaspin serum levels compared to NSTEMI p < 0.01. Conclusion: Rosuvastatin significantly increases vaspin serum levels in acute coronary syndrome. View Full-Text
Keywords: vaspin; acute coronary syndrome; NSTEMI; STEMI vaspin; acute coronary syndrome; NSTEMI; STEMI

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Al-kuraishy, H.M.; Al-Gareeb, A.I.; Al-Buhadilly, A.K. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases 2018, 6, 9.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top